<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Together with a detailed presentation of the physiological role of antithrombin III and a description of the pathological states in which it's acquired deficiency requires substitutional therapy with an antithrombin preparation, this report contains the results of a clinical trial of such a preparation which is in use under the name of Kybernin </plain></SENT>
<SENT sid="1" pm="."><plain>Patients with severe diseases and traumas, of a septic nature mostly, were included in the trial </plain></SENT>
<SENT sid="2" pm="."><plain>The experimental group includes 20 such patients treated with Kybernin, and the control group had 12 patients who did not receive this preparation </plain></SENT>
<SENT sid="3" pm="."><plain>The level of antithrombin III at the time of entering the study was an average of 40.1% in the experimental group, and 53.2% in the control group </plain></SENT>
<SENT sid="4" pm="."><plain>The mortality of the treated group was 45%, and in the control group it was 66.7% </plain></SENT>
<SENT sid="5" pm="."><plain>Clinical and laboratory results point to a favorable effect of Kybernin therapy in the suppression of <z:hpo ids='HP_0005521'>disseminated intravascular coagulation</z:hpo> </plain></SENT>
</text></document>